Sandoz stock enters Brazil with first semaglutide launch

Sandoz announced on Monday, November 9, 2026, that it had launched Owozy, its first semaglutide treatment, in Brazil. The company said in its press release that the product is intended for adults with insufficiently controlled type 2 diabetes.

Owozy was developed by Adalvo and received approval from Brazil's health regulator Anvisa on July 29, 2026. Local partner Biolab & Co will commercialize the once-weekly injectable treatment under a distribution and promotion agreement signed earlier this year.

GLP-1 entry opens a new market

Sandoz described Brazil as one of the world's largest and fastest-growing GLP-1 markets. The company cited an estimated market size of USD 2.7 billion and more than 16.5 million adults living with diabetes in the country. Owozy is supplied in a multi-dose disposable pre-filled pen and is approved for use alongside diet and exercise.

Chief Executive Richard Saynor called the launch a milestone for Sandoz and patients in Brazil. The announcement links the move to the GLP-1 strategy presented at the company's September 2026 Capital Markets Day, which also included early semaglutide launches in Brazil and Canada.

The near-term earnings effect remains limited. Sandoz said it does not expect a material financial contribution from the Brazilian semaglutide launch in 2026, making market access and future volume development more important than immediate sales for investors.

Sandoz stock trades below Xetra close

Sandoz stock traded at 90.68 euros on Lang & Schwarz at 11:21 CET on Wednesday, November 11, 2026, 2.05 percent below the Xetra close of Tuesday. Yahoo Finance identified D8Y.DE as the Xetra listing and showed the prior close at 92.58 euros.

Investors will focus on the speed of the Brazilian rollout, local competition and whether semaglutide can develop into a meaningful contributor to Sandoz's broader growth strategy. The company's statement provides no 2026 earnings uplift from this launch, so the main valuation question is the longer-term potential of the GLP-1 portfolio.

Swiss equity investors can follow the broader market backdrop through the SMI.

More news and analyses on Sandoz stock are available here.